ClinicalTrials.gg
CompletedNCT06836063Updated Apr 7, 2026

Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

A Phase 2 interventional study of Ropanicant and Placebo in Major Depressive Disorder (MDD), sponsored by Suven Life Sciences Limited. Completed at 35 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Suven Life Sciences Limited · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
214
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.

Enrollment
339th of 1,323
214 · median 70
Started
2025
with 69 others
Phase 2
271 of 1,500
45 open now
Registered
1,382nd of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 339th largest by enrollment of the 1,323 interventional ones that give a count, is one of 70 that started in 2025, is one of 271 in phase 2, and was the 1,382nd registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

210 more — sign in →

All 215 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

The primary objective is to evaluate the efficacy of Ropanicant at two different dosage levels compared to placebo in patients with Major Depressive Disorder (MDD).

Read the detailed description

This is a Phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of Ropanicant versus placebo in patients with MDD. The study will be conducted at multiple centers located in the US.

This study consists of a 4-weeks screening period, 6-weeks treatment period, and a 2-weeks follow-up period. Approximately 195 patients will be randomly assigned to receive Ropanicant Dose Level 1 bid or Dose Level 2 bid, or placebo bid for 6 weeks in a ratio of 1:1:1 (65 patients in each treatment group).

03

Conditions studied

  • Major Depressive Disorder (MDD)

Keywords

  • SUVN-911
  • α4β2
  • Ropanicant
  • MDD
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must meet the , Fifth Edition, Text Revision (DSM-5-TR) criteria for MDD without psychotic features based on the Mini International Neuropsychiatric Interview (MINI) with a current major depressive episode of at least 4 weeks of duration but no longer than 12 months.
  • Patients must have a Clinical Global Impression-Severity (CGI-S) score of ≥4.
  • Patients must have a Structured Interview Guide for the Hamilton Depression Rating Scale (SIGH-D) score of ≥20.
  • Patients must have a Snaith-Hamilton Pleasure Scale (SHAPS) score of ≥20.
  • Patients must have vision and hearing (corrected if needed) sufficient to comply with the testing procedures.

Exclusion criteria

Exclusion Criteria:

  • Patients who meet criteria for treatment-resistant depression (TRD) during the current major depressive episode, which is defined as being nonresponders (\<50% of symptom improvement) to 2 or more depression treatment periods of adequate dose and duration.
  • Patients not in good general health with abnormalities as assessed by the investigator and determined by physical examination results, neurological examination results, results, or laboratory assessments.
  • Female patients who are pregnant, planning to become pregnant during the study or within 30 days after the last administration of study drug, or breastfeeding.
  • Patients with bradycardia (\<50 bpm) or tachycardia (>100 bpm) on the ECG results.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
214 participants (actual)

Study arms

  • Experimental
    Ropanicant Dose Level 1

    Drug: Ropanicant

  • Experimental
    Ropanicant Dose Level 2

    Drug: Ropanicant

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugRopanicant

    Tablet dosage form, twice a day

    Also known as: SUVN-911

  • DrugPlacebo

    Matching placebo tablets, twice a day

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score at Week 6

    The MADRS is a clinician-rated scale to assess depressive symptoms which consists from 10 items. The time frame for this scale is the past 7 days. Each item is scored on 7-point scale (0 \[absence of symptoms\] to 6 \[severe\]). The total score is the sum of 10 items and can take range from 0 to 60. A higher score represents a higher severity of the level of depression.

    Time frame: Baseline to Week 6

Secondary outcomes

  1. Change from Baseline in Clinical Global Impression-Severity (CGI-S) score at Week 6

    The CGI-S will be used to rate the severity of each patient's illness related to depressive symptoms on a 7-point scale, which includes the following gradations: 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill.

    Time frame: Baseline to Week 6

Other outcomes

  1. Change from Baseline in Snaith-Hamilton Pleasure Scale (SHAPS) score at Week 6

    The SHAPS is a subject self- administered scale to measure hedonic capacity which consists of 14 items (total scores range from 14 to 56). Each item has a set of 4 possible responses (Strongly or Definitely Agree, Agree, Disagree and Strongly Disagree). A total score is derived by summing the responses to each item. A higher score represents a higher level of anhedonia.

    Time frame: Baseline to Week 6

07

Study locations

35 sites
  • Woodland International Research Group LLC
    Little Rock, Arkansas 72211, United States
  • Woodland Research Northwest
    Rogers, Arkansas 72758, United States
  • Advanced Research Center, Inc.
    Anaheim, California 92805, United States
  • ProScience Research Group
    Culver City, California 90230, United States
  • Behavioral Research Specialists, LLC
    Glendale, California 91206, United States
  • Synergy San Diego
    Lemon Grove, California 91945, United States
  • Excell Research, Inc.
    Oceanside, California 92056, United States
  • ATP Clinical Research
    Orange, California 92866, United States
  • Collaborative Neuroscience Research
    Torrance, California 90504, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
  • Premier Clinical Research Institute, Inc
    Miami, Florida 33122, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • Panhandle Research and Medical Clinic LLC
    Pensacola, Florida 32503, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • CenExcel iResearch LLC
    Decatur, Georgia 30030, United States
  • CenExcel iResearch LLC
    Savannah, Georgia 31405, United States
  • Chicago Research Center Inc.
    Chicago, Illinois 60634, United States
  • Neurobehavioral Medicine Group
    Bloomfield Hills, Michigan 48302, United States
  • Precise Research Centers
    Flowood, Mississippi 39232, United States
  • Midwest Research Group
    Saint Charles, Missouri 63304, United States
  • Redbird Research, LLC
    Las Vegas, Nevada 89119, United States
  • Vector Clinical Trials
    Las Vegas, Nevada 89128, United States
  • Center for Emotional Fitness
    Cherry Hill, New Jersey 08002, United States
  • Hassman Research Institue
    Marlton, New Jersey 08053, United States
  • SPRI Clinical Trials, LLC
    Brooklyn, New York 11235, United States
  • Neurobehavioral Research Inc.
    Cedarhurst, New York 11516, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10312, United States
  • Eximia Research-NC, LLC
    Raleigh, North Carolina 27607, United States
  • Sooner Clinical Research, Inc
    Oklahoma City, Oklahoma 73116, United States
  • Clinical Neuroscience Solutions Inc.
    Memphis, Tennessee 38119, United States
  • Community Clinical Research, Inc.
    Austin, Texas 78754, United States
  • North Texas Clinical Trials, LLC
    Fort Worth, Texas 76104, United States
  • Memorial Hermann Village
    Houston, Texas 77043, United States
  • Core Clinical Research
    Everett, Washington 98201, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Feb 2026, 7 months.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 7 months is below that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2025
First posted
Feb 20, 2025
StartActual
Jul 15, 2025
Primary completionActual
Feb 23, 2026
CompletionActual
Feb 23, 2026
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06836063
Lead sponsor
Suven Life Sciences Limited
Responsible party
Sponsor
First posted
Feb 20, 2025
Start date
Jul 15, 2025
Primary completion
Feb 23, 2026
Completion
Feb 23, 2026
Last update
Apr 7, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion